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reservoirs that are inaccessible to antiretroviral therapy. A
potential curative strategy is to reactivate viral gene expression
in latently infected cells. However, no drug so far has proven to
be successful in vivo in reducing the reservoir, and therefore
new anti-latency compounds are needed. We explored the
role of microRNAs (miRNAs) in latency maintenance and their
modulation as a potential anti-latency strategy. Latency models
based on treating resting CD4 T cells with chemokine (C-C
motif) ligand 19 (CCL19) or interleukin-7 (IL7) before HIV
infection and next-generation sequencing were used to identify
themiRNAs involved inHIV latency.We detected four upregu-
lated miRNAs (miRNA-98, miRNA-4516, miRNA-4488, and
miRNA-7974). Individual or combined inhibition of these
miRNAs was performed by transfection into cells latently
infected with HIV. Viral replication, assessed 72 h after trans-
fection, did not increase after miRNA modulation, despite
miRNA inhibition and lack of toxicity. Furthermore, the com-
bined modulation of five miRNAs previously associated with
HIV latency was not effective in these models. Our results do
not support the modulation of miRNAs as a useful strategy
for the reversal of HIV latency. As shown with other drugs,
the potential of miRNA modulation as an HIV reactivation
strategy could be dependent on the latency model used.Received 11 December 2018; accepted 10 June 2019;
https://doi.org/10.1016/j.omtn.2019.06.006.
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According to the United Nation’s HIV/AIDS program UNAIDS, in
2015, 35 million people worldwide were affected by HIV.1 Antiretro-
viral therapy (ART) can successfully suppress HIV viremia and signif-
icantly delay disease progression. However, the infection remains
incurable, and lifetime treatment is required because of viral persis-
tence in latent reservoirs that are not accessible to ART and are
undetectable by the immune system.2,3 Latency is a reversible,
nonproductive state of infection of individual cells, and therefore
the latently infected cells do not produce infectious virus particles
but retain the capacity to do so.4 This life-long latent reservoir isMolecular Therap
This is an open access article under the CC BY-NC-quickly established in vivo after infection and consists mainly of
several populations of memory resting (r)CD4 T cells, including cen-
tral memory, transitional, and effector memory cells.5,6 The reservoir
size is quite small in patients on ART, estimated at 10–100 replica-
tion-competent latent proviruses per million rCD4 T cells.7 However,
it is sufficient to refuel viral replication after an ART interruption.8
A plausible strategy for curing HIV is to activate viral gene expression
in these latently infected cells, using pharmacological drugs known as
latency-reversing agents (LRAs). Viral reactivation should take place
along with the removal of HIV-expressing cells via the action of im-
mune cytotoxic effector cells: a strategy commonly known as “shock
and kill.” To avoid undesirable side effects, only approaches that
trigger HIV reactivation with minimal cellular activation may be
considered for therapeutic use.9,10To date, a major problem following
LRA treatment has been that ex vivo assays show great diversity in the
HIV reactivation responses that do not always correlate with the re-
sults of in vitro assays.11–13 Therefore, new anti-latency compounds
that effectively reduce the size of the HIV reservoir in vivo are needed.
However, because of the low frequency of latently infected cells
in vivo, the use of in vitro models of latency is essential in the search
for new anti-latency compounds prior to their testing in ex vivo and
in vivo assays. These latency in vitromodels must allow efficient viral
integration while maintaining low levels of viral expression in rCD4




Figure 1. Establishment and Characterization of
HIV-1 Latency Models Based on CCL19 or IL-7
Treatment
rCD4 lymphocytes were treated with CCL19 (29 nM) or
IL-7 (5 nM) for 5 days, infected with X4-tropic NL4-3
HIV-1 strain, and cultured for an additional 4 days before
use in modulating expression of cellular miRNAs. (A) A
schematic of the HIV-1 primary-cell latency model. (B)
qPCR analysis of HIV-1 proviral integration. (C) p24/gag
levels in the supernatant of non-activated HIV-1-infected
cells were assessed to measure basal replication. Sta-
tistical significance was determined by Kruskal-Wallis
test with Dunn’s Multiple Comparison post-test analysis
(*p < 0.05 and ***p < 0.001). Data in (A) and (B) are the
mean ± SEM from eight independent experiments.
Comparison are referred to non-treated cells. (D) A vector
expressing a non-relevant, scrambled anti-miRNA and
the reporter FAM (i-scrambled-miRNA-FAM) was trans-
fected as a control of transfection efficiency. Data are the
mean ± SEM (graphs) or a representative experiment
(histogram). (E) HIV-1 replication was measured as p24/
gag levels in the supernatant of HIV-1 latently infected
cells after the expression of i-scrambled-miRNA-FAM
vector. Data are the mean ± SEM of two independent
experiments.
Molecular Therapy: Nucleic Acidsthe next, as it is unknown which is most relevant or harbors the best
physiological mechanism of latency.14
MicroRNAs (miRNAs) are small, endogenous, non-coding RNA
transcripts of 20–23 nt involved in the transcriptional regulation of
gene expression.15,16 They have been shown to regulate the persis-
tence and reactivation of HIV reservoirs through the deregulation
of specific functional pathways important for HIV replication,17 but
few data are available. The miRNAs involved in HIV infection are
classified as viral or host encoded and then are further divided into
those that target HIV transcripts directly or that indirectly affect
the viral cycle through the regulation of cellular factors.18 Changes
in the host’s miRNA profile in response to HIV latency persistence
have been reported,19,20 and notably, miRNA-29 has already been
suggested as a good candidate for incorporation into HIV eradication
strategies.20 Furthermore, the simultaneous inhibition of miRNA-28,324 Molecular Therapy: Nucleic Acids Vol. 17 September 2019miRNA-125b, miRNA-150, miRNA-223, and
miRNA-382 has also been shown to reactivate
viral replication in ex vivo assays of rCD4 T
lymphocytes isolated from ART-treated HIV-
infected patients.19 However, there is no agree-
ment on which specific miRNAs are involved in
viral latency and reactivation, and there have
been several contradictory results, including
which miRNAs have an exclusive tendency to-
ward downregulation.21,22
In the current work, different in vitro latency
models and next-generation sequencing (NGS)
have been used to find new miRNAs involvedin latency persistence and to explore the modulation of these miRNAs
as a potential novel anti-latency strategy.
RESULTS
Establishment and Validation of the HIV Latency Models Used in
This Study
In this study, we characterized HIV latency models based on exposing
rCD4 T cells to chemokine (C-C motif) ligand 19 (CCL19) or inter-
leukin 7 (IL-7) before HIV in vitro infection. A schematic of the
models is shown in Figure 1A. Briefly, rCD4 T cells were treated
with CCL19 or IL-7 for 5 days, infected with an X4-tropic NL4-3
HIV clone, and cultured for an additional 4 days in the presence of
CCL19 or IL-7 and with a low concentration of IL-2.
Viral integration and basal replication were assessed at day 4. Proviral
integration significantly increased 36- and 659-fold in CCL19- and
AB
Figure 2. Differentially Expressed miRNAs Are Shared by Both CCL19- and
IL-7-Based HIV-1 Latency Models
(A) A Venn diagram showing the differentially expressed miRNAs between all
cell conditions studied. A subset of four deregulated miRNAs (miRNA-4488,
miRNA-7974, miRNA-98-5p, and miRNA-4516) is shared by the CCL19- and
IL-7-treated, HIV-1-infected rCD4 T lymphocytes. (B) The expression levels of
miRNA-98, miRNA-4516, and miRNA-7974 were analyzed by qRT-PCR in
CCL19- and IL-7-treated, HIV-1-infected T cells. Levels of miRNA-4488 could not
be measured, as the commercial oligonucleotides were not accurate. 5S was
used as the housekeeping gene. Data are the mean ± SEM and are expressed as
the relative percentage of miRNAs levels. Comparisons were performed between
HIV-1-infected and uninfected cells within the same treatment (CCL19 versus
CCL19-HIV cells or IL-7 versus IL-7-HIV-1 cells). Statistical significance
was calculated by two-way ANOVA, followed by the Bonferroni post-test analysis
(*p < 0.05, ***p < 0.001).
www.moleculartherapy.orgIL-7-treated cells, in comparison to non-treated HIV-infected cells
(p < 0.05 and p < 0.001, respectively; Figure 1B). In contrast to the
high integration levels obtained, viral replication was increased by
only 2.2- and 6.1-fold in CCL19- and IL-7-treated cells, compared
with non-treated cells (p < 0.05; Figure 1C). As a positive control,
phytohemagglutinin (PHA)/IL-2- and IL-2-treated cells were used
in CCL19- and IL-7-based models, respectively (Figure S1). In com-
parison to untreated cells, proviral integration and replication
increased 26- and 110-fold, respectively, in PHA/IL-2-treated cells
but just 19- and 4.4-fold, respectively, in IL-2 treated cells in accor-
dance with the fact that HIV replicates mainly in activated CD4
T cells.23–25A vector expressing a non-relevant, scrambled anti-miRNA, together
with the reporter carboxyl fluorescein (FAM) (inhibitory [i]-scram-
bled-miRNA-FAM), was transfected into the HIV-infected CD4
T cells, which was, on average, 29.4% of cells (Figure 1D). The expres-
sion of i-scrambled-miRNA-FAM did not affect HIV replication
in CCL19- or IL-7-treated cells, since the induced p24/gag levels
were similar to those shown in the H2O-transfected cells used as
the negative control (Figure 1E).
Identification of Novel miRNAs Potentially Involved in HIV
Latency Persistence Using NGS
These HIV latency in vitromodels allowed us to identify key miRNAs
that play a role in avoiding HIV transcription and/or maintaining viral
latency. At day 4 after HIV infection, RNA was extracted in two inde-
pendent experiments and subjected to NGS. miRNA profiles from
non-treated, CCL19-treated, or IL-7-treated HIV-infected rCD4
T cells were compared with those obtained from uninfected cells.
Changes in miRNAs expression were considered significant when
the fold change was >0.4 or <0.4 and the adjusted p value (false
discovery rate [FDR]) was <0.001. Only deregulated miRNAs found
in both latency models and not present in the list of deregulated
miRNAs of non-treated HIV cells were selected for further modula-
tion. Based on these criteria, four upregulated miRNAs (miRNA-98-
5p [referred to henceforth as miRNA-98], miRNA-4516, miRNA-
7974, and miRNA-4488) were selected (Figure 2A; Table 1).
The expression levels of miRNA-98, miRNA-4516, and miRNA-7974
were analyzed by qRT-PCR in CCL19- and IL-7-treated, HIV-in-
fected rCD4 T lymphocytes (Figure 2B). miRNA-4488 could not be
measured or modulated, as the synthetic inhibitors and oligonucleo-
tides were neither accurate nor robust enough. The oligonucleotide
for miRNA-4488 amplification did not yield a measurable Ct value,
even after 55 amplification cycles (data not shown). Therefore,
miRNA-4488 was excluded from further study. The relative percent-
age of miRNA levels was calculated between infected and non-
infected cells within the same cytokine treatment (CCL19 or IL-7).
Consistent with NGS, qRT-PCR showed that miRNA-98, miRNA-
4516, and miRNA-7974 expression was enhanced to 361%, 467%,
and 609%, respectively, in the CC19-treated infected cells (p <
0.001; Figure 2B). In the IL-7-based latency model, miRNA-98 and
miRNA-4516 expression levels were enhanced to 229% and 785%
(p < 0.05 and p < 0.001), respectively (Figure 2B). However, the
enhanced expression of miRNA-7974 was not confirmed in the
IL-7-treated infected rCD4T cells in comparison to the uninfected
IL-7 cells.
The Specific Inhibition of the Upregulated miRNAs in Latently
Infected rCD4 T Cells Did Not Enhance HIV Replication
The cells latently infected with HIV were challenged for virus reacti-
vation by modulating the selected miRNAs for 72 h (Figure 1A). Spe-
cific inhibitors of the selected human miRNA-98, miRNA-4516, and
miRNA-7974 were transfected alone or combined in CCL19- or IL-7-
treated cells 4 days after HIV infection. Vehicle-transfected, latently
infected cells were used as the negative control. Phorbol 12-myristateMolecular Therapy: Nucleic Acids Vol. 17 September 2019 325
Table 1. Differentially Expressed miRNAs in Non-, CCL19-, or IL-7-Treated
rCD4 HIV-Infected Cells, WhenComparedwith the Equivalent Non-infected
Controls
Name logFC logCPM p Value FDR
Non-treated rCD4 versus Non-treated HIV rCD4
hsa-miR-210-3p 3.46 7.43 5.62E109 2.06E106
hsa-miR-126-5p 1.5 6.11 1.97E23 3.6E21
hsa-miR-4532 1.41 6.51 1.04E18 1.26E16
hsa-miR-143-3p 2.87 5.41 4.68E09 4.28E07
hsa-miR-210-5p 2.31 3.14 1.74E08 0.00000127
hsa-miR-223-3p 1.96 6.64 6.66E07 0.0000406
hsa-miR-126-3p 1.69 3.26 0.00000249 0.0001
hsa-miR-150-3p 0.499 7.71 0.00000522 0.0002
rCD4-CCL19 versus rCD4-CCL19-HIV1
hsa-miR-4532 1.23 6.68 5.49E17 2.04E14
hsa-miR-4488a 1.42 4.45 2.97E09 5.52E07
hsa-miR-223-3p 2.32 6.86 6.07E09 7.51E07
hsa-miR-126-5p 1.32 6.58 9.11E09 8.45E07
hsa-miR-1307-5p 0.6545 9.2 1.48E08 0.0000011
hsa-miR-7974a 4.59 3.48 4.61E08 0.00000285
hsa-miR-143-3p 3.11 6.08 8.22E08 0.00000436
hsa-miR-210-3p 2.23 8.49 0.00000197 0.0000914
hsa-miR-98a 0.4189 9.95 0.00000699 0.0003
hsa-miR-4516a 1.25 3.66 0.000013 0.0005
IL-7-treated rCD4 versus IL-7-treated HIV rCD4
hsa-miR-34a-5p 1.7 6.62 2.81E22 1.13E19
hsa-miR-4532 1.79 6.93 1.38E13 2.79E11
hsa-miR-98a 0.7838 10.28 1.24E11 1.68E09
hsa-miR-150-5p 0.774 16.98 4.04E10 4.08E08
hsa-miR-4284 3.3 2.81 1.28E09 8.61E08
hsa-miR-4492 1.43 4.66 1.23E09 8.61E08
hsa-miR-328-3p 0.992 6.36 2.43E09 0.00000014
IL-7-treated rCD4 versus IL-7-treated HIV rCD4
hsa-miR-34a-5p 0.7805 16.19 2.15E08 0.00000108
hsa-miR-140-3p 0.467 12.02 7.99E08 0.00000359
hsa-miR-142-3p 0.475 12.62 1.78E07 0.00000717
hsa-miR-143-3p 2.51 5.44 3.05E07 0.0000112
hsa-miR-130b-3p 1.19 5.7 5.31E07 0.0000179
hsa-miR-4488a 2.05 4.38 7.56E07 0.0000235
hsa-miR-182-5p 1.07 5.97 0.00000105 0.0000304
hsa-let-7d-5p 0.6271 8.96 0.00000285 0.0000768
hsa-miR-223-3p 1.64 6.64 0.00000543 0.0001
hsa-miR-484 0.489 9.4 0.0000198 0.0003
hsa-miR-24-3p 0.5341 8.93 0.0000121 0.0003
hsa-miR-301b-3p 1.16 3.76 0.0000121 0.0003
hsa-miR-4485-3p 1.46 4.82 0.0000143 0.0003
(Continued)
Table 1. Continued
Name logFC logCPM p Value FDR
hsa-miR-4516a 1.4 4.11 0.0000146 0.0003
hsa-miR-29c-3p 0.447 11.38 0.0000186 0.0003
hsa-miR-7704 0.838 5.82 0.000013 0.0003
hsa-miR-22-3p 0.7297 13.02 0.0000193 0.0003
hsa-miR-30e-3p 0.628 8.74 0.0000335 0.0005
hsa-miR-21-3p 0.5902 12.75 0.0000431 0.0007
hsa-miR-7974a 1.33 4.16 0.0000527 0.0007
hsa-miR-151a-3p 0.413 10.11 0.0000479 0.0007
hsa-miR-194-5p 0.541 8.57 0.0000523 0.0007
hsa-miR-30c-5p 0.392 10.68 0.0000762 0.001
hsa-miR-20b-5p 0.8422 6.21 0.000082 0.0011
hsa-miR-625-5p 0.8671 4.66 0.0000947 0.0012
hsa-miR-335-3p 1.14 6.07 0.0001 0.0013
Data are fold change of deregulated miRNAs (logFC), the log of counts per million of
reads (logCPM), the p value, and the adjusted p value FDR (false discovery rate).
amiRNAs shared by both latency models and not presented in non-treated cells.
Molecular Therapy: Nucleic Acids
326 Molecular Therapy: Nucleic Acids Vol. 17 September 201913-acetate (PMA) was used as a positive control for viral reactivation
and was added to mock-transfected cells for the last 18 h. The effi-
ciency of inhibition was evaluated 72 h later for each miRNA by
qRT-PCR (Figure 3A; Table 2). Data are the relative percentage of
miRNA levels in comparison to mock cells. In the CCL19 model,
the expression levels of miRNA-98, miRNA-4516, and miRNA-
7974 were reduced to 3.4%, 48.0%, and 32.2%, respectively, after
combining all miRNA inhibitors. Similarly, the expression levels of
miRNA-98, miRNA-4516, and miRNA-7974 were reduced to 8.8%,
53.9%, and 35.2%, respectively, after the combined modulation. In
both latency models, the combination of all the miRNA inhibitors
yielded similar inhibition of each miRNA as when used individually
(Table 2).
Cell viability and HIV replication were assessed 72 h after miRNA
inhibition. Cell viability was not affected by miRNA-98, miRNA-
4516, or miRNA-7974 inhibition, alone or combined, in CCL19- or
IL-7-treated HIV-infected cells (Figure 3B). PMA was added as a pos-
itive control of viral reactivation for the last 18 h. HIV replication was
enhanced more than 5-fold after PMA stimulation, in both latency
models (Figure 3C). However, HIV latency could not be reversed after
the inhibition of miRNA-98, miRNA-4516, and miRNA-7974, alone
or combined, in either CCL19- or IL-7-treated cells (Figure 3C), as no
significant increase in HIV replication was detected.
The Inhibition of miRNA-98, miRNA-4516, and miRNA-7974 Did
Not Enhance the Replication of R5-Tropic HIV, Alone or
Combined with LRAs
Most of the viruses that establish the reservoir during early infection
are CCR5 tropic.26,27 Therefore, rCD4 T cells treated with CCL19
were infected with the JR-CSF HIV strain and then challenged for re-
activation by inhibiting altogether the expression of miRNA-98,
AB
C
Figure 3. Modulation of Shared miRNAs in HIV-1-
Infected CCL19- or IL-7-Treated rCD4 T
Lymphocytes
Primary rCD4 T lymphocytes were treated with CCL19 or
IL-7 for 5 days, infected with X4-tropic NL4-3 HIV-1, and
cultured for an additional 4 days. Then, miRNA-98,
miRNA-4516, and miRNA-7974 were inhibited by the
transfection of specific anti-miRNA-98, anti-miRNA-
4516, and anti-miRNA-7974. Cells were cultured for
3 days and PMA was added for the last 18 h. (A)
Expression levels of miRNA-98, miRNA-4516, and
miRNA-7974 were measured by qRT-PCR 72 h after
transfection of all the anti-miRNAs combined. Data are
the mean ± SEM and are expressed as the percentage of
change, with 5S levels used as the reference. (B) Cell
viability was measured in HIV-1 latently infected rCD4
T cells 3 days after the inhibition of miRNA-98, miRNA-
4516, and miRNA-7974. Data are represented as
absolute values of relative light units (RLUs). (C) HIV-1
replication was assessed by quantifying p24/gag levels in
the culture supernatant 72 h after miRNA modulation or
18 h after PMA activation. Statistical significance was
determined by using the Kruskal-Wallis test with Dunn’s
multiple comparison post-test analysis (*p < 0.05). Mock
cells served as the reference. Data from four independent
experiments are shown.
www.moleculartherapy.orgmiRNA-4516, and miRNA-7974. Vehicle-transfected, latently in-
fected cells were used as mock cells. PMA was used as a positive viral
control. The efficiency of inhibition was evaluated 72 h later for each
miRNA by qRT-PCR (Figure 4A; Table 2). Data are the relative per-
centage of miRNA levels in comparison to mock cells. The expression
levels of miRNA-98, miRNA-4516, and miRNA-7974 were reduced
to 0.5%, 39.3%, and 22.9%, respectively, after combining all miRNA
inhibitors. HIV replication was enhanced 9.9-fold after PMA stimu-
lation (p < 0.05), but was not reversed after the inhibition of miRNA-
98, miRNA-4516, and miRNA-7974 (Figure 4B).
The combination of LRAs is considered a plausible strategy to reduce
the size of the HIV reservoir in vivo.11,28 We therefore studied
whether combining the inhibition of these miRNAs with one of the
most common LRAs would reverse HIV latency. CCL19-treatedMolecular Therapand JR-CSF-infected rCD4 T cells were trans-
fected with the inhibitors of miRNA-98,
miRNA-4516, and miRNA-7974 together (all-
i-miRNAs) and then treated with romidepsin,
panobinostat, or bryostatin-1 during the last
18 h (Figure 4C). Mock-transfected cells were
also treated. PMA was used as a positive control
of viral reactivation, which was enhanced
around 9.0-fold in both mock and all-i-
miRNA-transfected cells (Figure 4C). Viral
replication was enhanced 14.4- and 8.5-fold,
respectively, in mock and all-i-miRNA-trans-
fected cells treated with romidepsin. This repre-sents a 0.7-fold reduction in all-i-miRNA-transfected cells versus the
mock ones (p < 0.01). HIV replication in mock cells treated with
panobinostat or bryostatin-1 was enhanced 10.9- and 7.9-fold,
respectively, and was similar overall in cells with inhibited miRNAs.
Inhibition of miRNAs Previously Described to Be Associated
with HIV Reactivation Did Not Reverse HIV Latency in CCL19-
and IL-7-Based In Vitro Models
It has been shown that combined inhibition of miRNA-28, miRNA-
125b, miRNA-150, miRNA-223, and miRNA-382 resulted in HIV
replication in cells in vitro transfected with an NL4.3-expressing
vector and also in rCD4 T cells isolated from HIV-infected individ-
uals on ART.19 Therefore, we evaluated whether inhibition of these
miRNAs would affect HIV replication in the latency models used in
this study.y: Nucleic Acids Vol. 17 September 2019 327
Table 2. Expression Levels of Indicated miRNAs Were Measured by qRT-PCR 72 h after Transfection of Each Anti-miRNA, Individually or Combined in
CCL19- or IL-7-Based HIV Latency Models
HIV Latency Model miRNA Modulated miRNA-98 miRNA-4516 miRNA-7974
% miRNA Expression Levels (As Shown in Figure 3)
mock 100 ± 0.0 100 ± 0.0 100 ± 0.0
rCD4 T cells i-miRNA-98 3.3 ± 0.7
CCL19 treated i-miRNA-4516 75.6 ± 11.6
HIV infected i-miRNA-7974 46.8 ± 10.5
all-i-miRNA together 3.4 ± 0.9 48.0 ± 19.00 32.2 ± 15.9
mock 100 ± 0.0 100 ± 0.0 100 ± 0.0
rCD4 T cells i-miRNA-98 3.3 ± 0.7
IL-7 treated i-miRNA-4516 75.6 ± 11.6
HIV infected i-miRNA-7974 46.8 ± 10.5
all-i-miRNA together 3.4 ± 0.9 48.0 ± 19.00 32.2 ± 15.9
% miRNA Expression Levels (As Shown in Figure 4)
rCD4 T cells, CCLL19 Mock 100 ± 0.0 100 ± 0.0 100 ± 0.0
HIV-infected all-i-miRNA together 0.5 ± 0.1 39.3 ± 15.1 22.9 ± 1.5
% miRNA Expression Levels (As Shown in Figure 5)
HIV Latency Model miRNA Modulated miRNA-28 miRNA-125b miRNA-150 miRNA-223 miRNA-382
mock 100 ± 0.0 100 ± 0.0 100 ± 0.0 100 ± 0.0
rCD4 T cells i-miRNA-28 25. ± 1.3
CCL19 treated i-miRNA-125b 1.0 ± 0.4
HIV infected i-miRNA-150
i-miRNA-223 5.8 ± 3.1
i-miRNA-382 6.6 ± 4.1
all-i-miRNA together 3.1 ± 0.5 1.7 ± 1.1 3.8 ± 1.7 1.4 ± 0.2
mock 100 ± 0.0 100 ± 0.0 100 ± 0.0 100 ± 0.0
rCD4 T cells i-miRNA-28 7.4 ± 9.0
IL-7 treated i-miRNA-125b 1.6 ± 1.6
HIV infected i-miRNA-150
i-miRNA-223 3.9 ± 3.0
i-miRNA-382 7.7 ± 0.4
all-i-miRNA together 3.5 ± 2.2 0.3 ± 0.1 3.3 ± 2.4 8.1 ± 1.6
Data are the mean ± SEM, and are expressed as the percentage of change using 5S levels as a reference.
Molecular Therapy: Nucleic AcidsIn the CCL19-based model, the expression levels of miRNA-28,
miRNA-125b, miRNA-150, miRNA-223, and miRNA-382 were
reduced to 3.1%, 1.7%, 0.1%, 3.8%, and 1.4%, respectively, in the sam-
ple transfected with the inhibitors for each miRNA altogether (Fig-
ure 5A; Table 2).
A similar inhibition was achieved in IL-7-treated cells, with expres-
sion levels reduced to 3.5%, 0.3%, 0.05%, 3.3%, and 8.1% for
miRNA-28, miRNA-125b, miRNA-150, miRNA-223, and miRNA-
382, respectively, after combined inhibition (Figure 5A; Table 2).
Cell viability was not significantly affected in any experimental con-
dition (Figure 5B). HIV replication was not induced after individual
or combined inhibition of these miRNAs in either of the two models328 Molecular Therapy: Nucleic Acids Vol. 17 September 2019tested (Figure 5C). However, PMA stimulation induced HIV replica-
tion by around 2.5-fold in both models.
Prediction of Targets of These miRNAs Potentially Related to
HIV Latency
Putative targets of miRNA-98, miRNA-4516, miRNA-7974, and
miR-4488 were predicted by means of the miRDB and miRTarBase
databases. Common predicted targets are represented in Figures 6A
and 6B, respectively. As expected, prediction of targets was different,
depending on the database, due to different algorithms. miRDB was
less restrictive and identified polio virus receptor-like (PVRL)1
(CD111 or nectin-1) and MiRTarBase pointed out CDKN1A (p21)
as a common target for these four miRNAs. Functional enrichment
A B
C
Figure 4. Modulation of Shared miRNAs in rCD4 T
Lymphocytes Treatedwith CCL19 and Infectedwith
R5-Tropic HIV
Primary rCD4 T lymphocytes were treated with CCL19 for
5 days, infected with R5-tropic JR-CSF HIV-1, and
cultured for an additional 4 days. Then, miRNA-98,
miRNA-4516, and miRNA-7974 were altogether inhibited
by the transfection of specific anti-miRNA-98, anti-
miRNA-4516, and anti-miRNA-7974. The cells were
cultured for 3 days, and PMA or the indicated latency-
reversing agent (LRA) was added for the last 18 h. (A)
Expression levels of miRNA-98, miRNA-4516, and
miRNA-7974 were measured by qRT-PCR 72 h after
transfection of the combined anti-miRNAs. Data are the
mean ± SEM and are expressed as the percentage of
change, using 5S levels as the reference. (B) HIV-1
replication was assessed in the same cells by quantifying
p24/gag levels in the culture supernatant 72 h after
miRNA modulation or 18 h after PMA activation. Statisti-
cal significance was estimated using the Kruskal-Wallis
test with Dunn’s multiple-comparison post-test analysis
(*p < 0.05). Mock cells served as the reference. (C) HIV-1
replication was assessed by quantifying p24/gag levels in
the culture supernatant 72 h after miRNA modulation.
PMA or the indicated LRA was added for the last 18 h to
mock-transfected cells and to cells transfected with the
miRNA inhibitors (all-i-miRNAs). The LRAs used were
romidepsin (40 nM), panobinostat (30 nM), and bryosta-
tin-1 (10 nM). Statistical significance was studied using
two-way ANOVA with the Bonferroni post-test analysis;
differences between mock-transfected cells and cells
transfected with themiRNA inhibitors were not significant.
Data are from four independent experiments.
www.moleculartherapy.orgof the common targets was studied using the GOstats and Panther
databases (Figures 6C and 6D, respectively). Common targets of the
four miRNAs appeared to be involved in immune process, metabolic
process, or stimuli response. Using the same methodology, we
analyzed the common targets for the five miRNAs identified by
Huang et al.19 miRDB did not identified any common target and
miRTarBase identified TP53 as a common target for four of the five
miRNAs (Figure 6E).
Finally, the mRNA expression of the common miRNAs’ putative
targets nectin-1 and p21 was analyzed by qRT-PCR in CCL19-
and IL-7-treated cells infected with the NL4.3 strain of HIV,
compared with untreated cells (Figure 6F). Consistent with the
increased expression of the four selected miRNAs, nectin-1 and
p21 mRNA levels were downregulated 0.30- and 0.21-fold in the
IL-7 model (p < 0.05 and p < 0.01), respectively. In CCL19-treated
cells, nectin-1 and p21 levels were downregulated 0.81- and 0.57-
fold, respectively, although this decrease was not statistically
significant.Molecular TherapDISCUSSION
WeidentifiednovelmiRNAspotentially involved
in latency and explored their modulation as anew LRA approach for switching from viral latency to replication.
However, miRNAmodulation was an ineffective tool for HIV reactiva-
tion in our models of latency.
The profiling of miRNAs in HIV-infected T lymphocytes has been
suggested as a valuable tool to identify endogenous miRNAs suitable
for modulation to purge latently infected cells,18 but no study has
been published so far using in vitro models of HIV latency. In this
work, cellular miRNAs with a potential role in maintaining HIV la-
tency were identified using NGS in two independent latency models
that may be considered complementary, as suggested by another
study.14 The NL4.3 HIV strain was used and miRNAs that were
shown to be significantly deregulated in both latency models were
selected. However, neither the individual nor the combined modula-
tion of these miRNAs yielded viral replication in these HIV latency
models. In addition, in CCL19-treated cells, combined inhibition of
the selected miRNAs did not affect replication of R5-tropic HIV,
which is the phenotype of the viruses that establish the reservoir
in vivo.26,27 Furthermore, a combined treatment, including inhibitiony: Nucleic Acids Vol. 17 September 2019 329
AB
C
Figure 5.Modulation in the CCL19 and IL7Models of
miRNAs Previously Described as Being Associated
with Latency
Primary rCD4 T lymphocytes were treated with CCL19 or
IL-7 for 5 days, infected with X4-tropic NL4-3 HIV-1, and
cultured for an additional 4 days. Then, miRNA-28,
miRNA-125b, miRNA-150, miRNA-223, and miRNA-382
were inhibited by the transfection of specific anti-miRNA-
28, anti-miRNA-125b, anti-miRNA-150, anti-miRNA-
223, and anti-miRNA-382. Cells were cultured for 3 days,
and PMA was added for the last 18 h. (A) Expression
levels of miRNA-28, miRNA-125b, miRNA-150, miRNA-
223, and miRNA-382 were measured by qRT-PCR 72 h
after transfecting all the anti-miRNAs in combination. Data
are the mean ± SEM and are expressed as the percent-
age of change, using 5S levels as the reference. (B) Cell
viability was measured 72 h after modulation of the
miRNAs or 18 h after PMA activation. Data are absolute
values of RLUs. (C) HIV-1 replication was assessed
by quantifying p24/gag levels in the culture super-
natant 72 h after miRNA modulation or 18 h after PMA
activation. Statistical significance was determined by
using the Kruskal-Wallis test with Dunn’s multiple-com-
parison post-test analysis (*p < 0.05). Mock cells served
as the reference. Data are from three independent
experiments.
Molecular Therapy: Nucleic Acidsof the selected miRNAs and treatment with one of the best known
LRAs, i.e., romidepsin, panobinostat or bryostatin-1,13 led to the
same negative result, and therefore the hypothesis that miRNA mod-
ulation may reduce the threshold for viral reactivation was not
confirmed.
Both models used in the study fulfilled criteria previously shown to be
of importance for robust in vitroHIV latencymodels: the induction of
efficient viral integration, together with restricted viral replica-
tion.29,30 However, basal replication was around 2.5-fold higher in
IL-7- than in CC19-treated cells probably because viral integration
is dramatically higher in IL-7-treated cells, as an action of the cytokine330 Molecular Therapy: Nucleic Acids Vol. 17 September 2019itself, since IL-7 has been shown to reactivate
latent HIV in rCD4 T cells from infected indi-
viduals.31,32 However, this difference does not
seem relevant when compared to fully activated
cells treated with PHA/IL-2.
In any case, each model resembles different
physiological scenarios of HIV infection.
CCL19 is in vivo a ligand for CCR7, a molecule
constitutively expressed in lymphoid organs
that is essential in guiding the migration of
naive and memory T cells into lymphoid tissue
and in the clustering of T cells with dendritic
cells.33–35 Interestingly, the latent HIV infection
predominantly occurs in rCD4 T cells express-
ing CCR7,2,26,36 and therefore CCL19 is a crit-ical factor that conditions rCD4 T cells to HIV infection, integration,
and latency.29 For the in vitro CCL19-treated cells, the mechanism
associated with the establishment of latency is a rapid de-phosphor-
ylation of cofilin and the subsequent changes in polymerized actin.37
However, no clinical trial involving the treatment with CCL19 has
been implemented so far in ART-treated HIV patients or in other dis-
eases, and the relevance of these in vitro assays has not yet been
confirmed. On the other hand, IL-7 contributes to the maintenance
of HIV reservoirs via homeostatic proliferation,6 but it does not
disrupt viral latency in latently infected cells,38 because NF-kB
increased slightly and too insufficiently to reverse viral latency.39,40





Figure 6. Functional Implications of miRNAs
Associated with Latency Based on Prediction of
Targets
Predicted targets for miRNAs deregulated in CCL19-
and IL-7-based models performed with (A) miRDB or
(B) MiRTarBase databases. Common targets are
shown in Venn diagrams. The intersection of the
four sets indicates one common target for each data-
base: nectin-1 or p21, respectively, for the miRDB or
MiRTarBase. (C and D) Functional enrichment in the
biological process of the common targets identified in
(A) and (B), respectively, and studied using the Panther-
Go terms program. (E) Venn diagrams of predicted
targets for miRNAs previously described as being
associated with targets identified by the MiRTarBase
database. (F) Expression of mRNA encoding for nec-
tin-1 and p21 was analyzed by qRT-PCR in CCL19- or
IL-7-treated cells, infected with the HIV NL4.3 strain.
Non-treated cells were used as a negative control. 5S
was used as the housekeeping gene. Media and SEM
from three independent studies are shown. Statistical
significance was estimated by using the Kruskal-Wallis
test with Dunn’s multiple comparison post-test analysis
(*p < 0.05 and **p < 0.01).
www.moleculartherapy.orgfactor SAM and HD domain containing deoxynucleoside triphos-
phate triphosphohydrolase (SAMHD)1, abrogating its antiviral activ-
ity, increasing viral RT, and rendering CD4 T cells more susceptible to
HIV integration and to the establishment of latent infection.40 Several
clinical trials using IL-7 have been performed in HIV ART-treated in-
dividuals in order to increase the number and function of lympho-
cytes and to test IL-7 as a potential anti-latency drug.38,41–44 In
some of these assays, IL-7 induced expansion of CD4 T cells42–44
but failed to deplete the viral reservoir and even increased, at least
transiently, the HIV DNA copy numbers.43,44 This may be due to
the expansion of the pool of T CD4 cells containing provirus,38,42,44
but also to the phosphorylation of SAMHD1, leading to HIV integra-
tion and reservoir replenishment.40 Nevertheless, IL-7 treatment in
clinical trials occurred after HIV infection, whereas IL-7 exposure
in our in vitro assays occurred before the infection, and therefore
we cannot assume that the same mechanisms were acting.Molecular TherapTo our knowledge, this is the first report to
identify miRNAs associated with HIV latency
in in vitro latency models. The IL7 model in-
volves extensive miRNA alterations, since
HIV latency affected more than 30 miRNAs.
In contrast, the CCL19 model exhibited a
lower number of miRNAs associated with la-
tency. Remarkably, four miRNAs were identi-
fied in both models. These results strongly
suggest that the miRNA profile associated
with latency establishment and maintenance
could be model dependent, but a common
set of these regulators is always associated
with HIV latency. Further studies includingother latency models could be done to test this hypothesis. In addi-
tion, it is important to verify the information gained from in vitro
models within latently infected cells obtained from ART-treated
patients.45 In this regard, the quantitative viral outgrowth assay
(QVOA) currently remains the gold standard,46 but could not be
performed in this study because of the negative nature of our re-
sults. However, the reliability of our findings is supported by the
fact that the CCL19-based model may represent the best proxy
primary in vitro model currently available for analyzing the activa-
tion capabilities of LRAs, when compared to QVOA.47 Although
the same results have been achieved in both latency models,
it should be noted that both models cannot be regarded as
equals. The CCL19-based latency model has been widely character-
ized29,30,37,48,49 and used by others,47,50,51 whereas the IL-7-based
latency model has only recently been described,40,52 and its value
remains to be confirmed.y: Nucleic Acids Vol. 17 September 2019 331
Molecular Therapy: Nucleic AcidsThe importance of miRNA modulation in reversing HIV latency was
first shown ex vivo more than 10 years ago19 in rCD4 T cells from
ART-treated patients, but particular miRNAs in this context have
not been successfully implemented to date. This pioneer study
used constructions of 1.9- or 1.2-kb fragments from the 30 end of
HIV, including the reported EGFP gene to identify the miRNAs
involved in latency. In this study, miRNA-28, miRNA-125b,
miRNA-150, miRNA-223, and miRNA-382 downregulated tran-
scripts containing a 1.2-kb fragment from the HIV 30 UTR that
harbors target sequences for these miRNAs. Combined inhibition
of these miRNAs activated HIV replication.19 However, we were un-
able to replicate these results despite the successful modulation of the
same miRNAs. There were a number of differences between the two
studies: the previous study used transfection instead of infection, and
incomplete viral genomes that overall do not resemble a natural HIV
infection as crucial steps of the viral cycle including viral entry, retro-
transcription, and nuclear transport are missing. As explained above,
the establishment of latency in the in vitro models used in our study
relies on enabling retrotranscription and nuclear transport through
the abrogation of cofilin or SAMHD1. Despite of the suitability of
CCL19- and IL-7-based models, HIV replication was not altered after
simultaneous modulation of the five miRNAs previously identified.19
Indeed, our NGS approach did not indicate the modulation of any of
these miRNAs.
Our study, however, has not been the only controversial publication
in the context of miRNAs in HIV replication. As an example, contra-
dictory findings have been published in regard to the modulation of
the miRNA-17/92 cluster during HIV replication, probably because
of the different time points and half-lives of the cultures,22,53–55 which
resulted in a differential regulation of cellular pathways involved in
T cell activation. Indeed, only miRNA-143-3p and miRNA-10a-5p
exhibited similar trends of suppressed expression in different ap-
proaches.54,56 The effect of host miRNAs on HIV replication appears
to be highly dependent on the experimental parameters, the quantifi-
cation method, the type of cell, and the HIV variants.21,22,54,56 Our
results suggest that this principle might affect HIV latency as well.
Finally, HIV acute infections achieved by transfection of the NL4.3
clone have been shown to downregulate 312 host miRNAs, with no
upregulations observed.21 Our results, based on latent HIV infection
using a similar clone, gave downregulated and also a set of upregu-
lated miRNAs, suggesting that different miRNA profiles are exploited
during latent persistence. These differences may account for active
versus dormant infection but may also reflect the poor concordance
already described among studies describing the HIV-mediated mod-
ulation of host miRNAs.54,57 It is also worth pointing out that highly
expressed miRNAs may be important for normal cellular homeosta-
sis. Thus, using pooled anti-miRNAs to activate HIV in latently
infected cells could result in toxicities. However, we did not report
them.
The accuracy of the reagents used to modulate and amplify these
miRNAs may partially account for these unexpected results. In fact,332 Molecular Therapy: Nucleic Acids Vol. 17 September 2019miRNA-4488 could not be neither quantified nor modulated because
validated probes are not available yet. Specific inhibition of miRNA-
4516 and amplification of miRNA-7974 were also difficult to attain
with the provided commercial tools. We observed great variations
among the biological replicates. Technical replicates within each
biological sample reproduced the results and confirmed the disparity.
Replicate measurements are not independent tests and cannot pro-
vide evidence of the reproducibility of the results.58 Therefore, only
one value—the mean of all the technical replicates for each biological
sample was considered as a result to be represented and used in the
statistical analyses. Nevertheless, reasonable biological arguments
for the observed results are provided above.
In any case, none of the miRNAs identified in the present manuscript
directly controls genes involved in HIV latency. Altogether, our re-
sults indicated that the four miRNAs do not act cooperatively in
HIV latency establishment or reactivation and, in fact, do not share
many targets. Depending on the database, p21 and nectin-1 were
identified. Remarkably, nectin-1 and p21 mRNA levels were downre-
gulated in the IL-7-based model, and to a lower extent, also in CCL19
latently infected cells, strongly suggesting both proteins to be real
miRNAs targets. The cyclin-dependent kinase inhibitor p21 has
been linked to the inhibition of HIV replication.59 Indeed, p21 blocks
HIV replication at the RT step through the increase of the antiviral
activity of SAMHD160 and acts downstream of p53 in non-cycling
human macrophages.61 Accordingly, the four miRNAs here identi-
fied, through p21 modulation, could affect HIV replication more
than the establishment of viral latency. Particularly, the inhibition
of the four miRNAs would lead to p21 upregulation, and therefore
inhibition of HIV replication could be expected. Changes in HIV
replication after miRNA inhibition was not observed in our models
in correlation with this supposition. In any case, further experiments
should be done to test this hypothesis. Nectin-1 is a key protein in
cell-cell adhesion and acts also as a viral receptor of herpes simplex
virus (HSV) and Pseudorabies virus. Moreover, Nectin-1 is seques-
tered to adherent junctions and facilitates HSV infection in epithelial
cells exposed to HIV62 through the regulation of matrix metallopep-
tidases.63 In any event, the predicted cooperative regulation of nectin-
1, mediated by the miRNAs deregulated in our latency models, would
not affect HIV latency or replication, according to our findings.
Remarkably, functional analysis of the five miRNAs identified by
Huang et al.19 did not yield any cooperative common targets.
Consequently, because of this lack of functional cooperation, the
modulation of the five miRNAs in our models did not lead to HIV
reactivation. In summary, although we have identified differentially
expressed miRNAs associated with latency in two in vitro models,
the inhibition of these selected miRNAs, individually or combined,
was ineffective for HIV latency reversal in vitro. It could be that
miRNA modulation alone is not sufficient to reactivate HIV and
may be due to HIV’s counteracting mechanisms keeping a selective
pressure that stimulates latency preservation.
Overall, the number of miRNAs identified as potential tools in HIV
re-activation is growing, but the selection of particular miRNAs in




Human peripheral blood mononuclear cells (PBMCs) were isolated
from the blood of healthy donors by a Ficoll-Hypaque gradient (GE
Healthcare, Uppsala, Sweden). Human rCD4 T lymphocytes were
isolated with a CD4 T Cell Isolation Kit (Miltenyi Biotec, Cologne,
Germany) and the subsequent depletion of CD25+ and HLA-DR+
cells was performed using CD25 MicroBeads II and anti-HLA-DR
MicroBeads (Miltenyi Biotec), respectively.
Models for In Vitro HIV Latent Infections
Figure 1A shows a schematic of HIV latency models. The HIV infec-
tion of purified primary rCD4 T lymphocytes was performed as pre-
viously described, with minor modifications.29,30,37,40,52 Briefly, rCD4
T cells were initially cultured for 5 days in the presence of CCL19
(29 nM) or IL-7 (5 nM) (both from R&D Systems, Minneapolis,
MN) or left inactivated. HIV infection has been performed as previ-
ously described.64 Briefly, infectious supernatants of NL4.3 or JR-CSF
strains were obtained from a calcium phosphate transfection of 293T
cells with HIV plasmids and treated with DNase (QIAGEN, Hilden,
Germany) before infection. Then, the rCD4 T lymphocytes were
infected with 10 pg of p24 per million cells for 2 h with gentle rotation
at room temperature. The cells were centrifuged at 600 g for 30 min at
25C and then extensively washed with 1 PBS. HIV-infected cells
were cultured in RPMI supplemented with IL-2 (10 IU/mL)
(Sigma-Aldrich, St. Louis, MO, USA), together with CCL19 or IL-7
at the concentrations indicated above for an additional 4 days. At
this time, provirus integration and basal viral replication was assessed.
Integrated HIV was quantified as previously described.5,65 Briefly,
strong stop DNA was quantified using specific primers for the R
and U5 regions of the HIV long terminal repeat (LTR). Episomal
forms of 2-LTR and integrated HIV proviral DNA were quantified
by PCR on a LightCycler 480 Instrument II (Roche Diagnostics, Man-
nheim, Germany). A standard curve of integrated DNA from 8E5 cell
line was prepared, and CCR5 was used as the normalization gene.
Basal HIV replication was calculated by measuring the p24/gag anti-
gen in the culture supernatants with a commercial ELISA (Innotest
HIV Ag mAb; Fujirebio Europe, Ghent, Belgium) and a microplate
luminometer with Gen5 Data Analysis Software (Biotek, Winooski,
Vermont). For HIV reactivation assays, latently infected cells were
then transfected with inhibitors for specific miRNAs (Exiqon, Ved-
baek, Denmark), individually or combined as described below,
and expression was allowed for 3 days. PMA (12.5 ng/mL) (Sigma-
Aldrich) was used as a positive control of viral replication and added
to mock-transfected cells for the last 18 h. Supernatants and cell pel-
lets were collected to measure the HIV p24 antigen (Innotest HIV Ag
mAb) and miRNA expression levels (qRT-PCR).
Construction of miRNA Libraries and NGS
CCL19- or IL-7-treated rCD4 T cells latently infected with the HIV
NL4-3 strain from two independent donors were used. Non-treatedcells were also included as the negative control. At day 4 after HIV
in vitro infection, total RNA, preserving the small RNA fraction,
was extracted, using the mirVana miRNA Isolation Kit (Life Technol-
ogies, Thermo Fisher Scientific, Waltham, MA) according to the
manufacturer’s instructions. The quantity and quality of the RNAs
were evaluated with the Agilent 2200 TapeStation. High-throughput
sequencing was carried out on a HiScanSQ platform (Illumina Inc.,
San Diego, CA). Libraries for sequencing were prepared using TruSeq
Small RNA Sample Prep Kit V1 (Illumina), according to the TruSeq
Small RNA Sample Preparation Guide. Briefly, ligation of the 30
adaptor was conducted incubating 1 mg of total RNA from each sam-
ple with the adaptor for 2 min at 70C. Then the 50 adaptor was added
alongside by a truncated T4-RNA ligase 2 (New England Biolabs,
Ipswich, MA) for 1 h at 28C. Half of the ligation product was used
for RT with SuperScript II RT (Life Technologies) in a thermocycler
for 1 h at 50C. Next, enrichment of the cDNA was performed using
PCR cycling: 30 s at 98C; 11 cycles of 10 s at 98C, 30 s at 60C, and
15 s at 72C; a final elongation of 10 min at 72C; and a pause at 4C.
PCR products were resolved on 6% Novex Tris-Borate-EDTA (TBE)
PAGE gels (Life Technologies). miRNA fragments between 145 and
160 bp were cut from the polyacrylamide gel and extracted with a
MinElute gel extraction kit (QIAGEN), according to the manufac-
turer’s instructions. The libraries were visualized on a 2100 Bio-
analyzer with the High Sensitivity DNA kit (Agilent Technologies,
Santa Clara, CA) and quantified using qPCR with the Library Quan-
tification Kit (Master Mix and DNA Standards; Kapa Biosystems,
Wilmington, MA). The libraries were pooled, and 9 pM pool libraries
were sequenced to generate single-ended 50-bp reads. Low-quality
reads (Q < 30) and reads that contained only Illumina adapters
were filtered out from the raw data. Filtered reads were mapped
against the human hg19 reference genome using the Novoalign
program, which strips adapters from the reads before mapping and
detects hairpin structures in the mapped region. Unique mapping
reads, with a minimum length of 17 nt and a maximum of a single
mismatch, were obtained in a sequence alignment map (SAM) file
and then sorted, indexed, and converted to a binary alignment map
(BAM) file, using Samtools. The total count for each of the miRNAs
was obtained with HTSeq-count, using a gff (gene-finding format) file
with all human miRNA features from mirBase (release 21). Normal-
ization of miRNA counts and differential expression between treated
and non-treated cells was performed using the edgeR package from
Bioconductor. Then, dataset comparisons to obtain the differentially
expressed microRNA profiles were performed.
qRT-PCR Assays
The isolation of total RNA containing miRNAs was carried out using
the mirVana miRNA Isolation Kit (Life Technologies), and cDNA
was synthesized from 100 ng of total RNA using the miRCURY
LNA Universal RT microRNA PCR System (Exiqon), according to
the manufacturer’s instructions. cDNA synthesis was carried out un-
der the following conditions: 42C for 60 min and 95C for 5 min.
The expression levels of miRNA-98, miRNA-4516, miRNA-7974,
miRNA-28, miRNA-125b, miRNA-150, miRNA-223, and miRNA-
382 were quantified with a specific miRNA-LNA PCR primer setMolecular Therapy: Nucleic Acids Vol. 17 September 2019 333
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amplification of the putative targets nectin-1 and p21 have been
described.66,67 Small 5S rRNA was used as a housekeeping gene for
data normalization; a 5S rRNA PCR primer set (Exiqon) was used.
ExiLENT SYBR Green PCRMaster Mix (Exiqon) was used according
to manufacturer’s instructions. PCR cycle conditions were 95C,
10 min; 55 cycles: 95C, 10 s; and 60C, 1 min, with a subsequent
melting-curve analysis. All reactions were performed in a LightCycler
480 Real-Time PCR System (Roche Diagnostics). The Cts observed
for all the miRNAs were lower than 35, although miRNAs inhibition
rendered higher Cts, as expected. Data analysis was performed using
the second-derivative method. Once the Ct was obtained, data were
normalized with the Ct values of 5S rRNA and analyzed with the for-
mula 2DDCt, with mock-transfected cells as the reference control.
Electroporation and HIV Re-activation with LRAs
CCL19- or IL-7-treated rCD4 T cells were transfected 4 days after
HIV infection with synthetic inhibitors for specific human miRNAs,
alone or using the combinations described above, with the use of
a Gene Pulser Electroporator (Bio-Rad, Hercules, CA). In brief,
3 million cells were collected in 350 mL RPMI 1640 medium without
supplements and mixed with 100 nM each miRNA inhibitor. The
cells were transfected in a cuvette with a 4-mm electrode gap (Bio-
Rad) at 250 V, 950 microfarads, and maximum resistance. After
transfection, the cells were incubated for 72 h at 37C in supplemental
RPMI including IL-2 (10 IU/mL) together with CCL19 (29 nM) or
IL-7 (5 nM). A scrambled miRNA inhibitor control expressing 5-car-
boxyfluorescein (FAM) as a reporter gene (i-scrambled-miRNA-
FAM) (Power inhibitor negative control; Exiqon) (100 nM) was
used as the control of transfection efficiency and measured by flow
cytometry on a FACScalibur Flow Cytometer (BD Biosciences, San
Jose, CA), using CellQuest software. PMA was used as a positive con-
trol for HIV replication and was added to mock-transfected cells for
the last 18 h. In some experiments, PMA or an LRA was added to
mock-transfected cells or to cells transfected with inhibitors for all
the selected miRNAs during the last 18 h, before harvesting. The
LRAs and concentrations used were romidepsin (40 nM), panobino-
stat (30 nM), and bryostatin-1 (10 nM).13
Cell Viability
Cell viability was measured in latently infected rCD4 T lymphocytes
after inhibition of selected miRNAs using a CellTiter-Glo Lumines-
cent Cell Viability Assay (Promega, Madison, WI). Briefly, 2  105
cells were incubated for 10 min at room temperature in CellTiter-
Glo Reagent, which contained lysis buffer and thermostable lucif-
erase. The luminescent signal correlated with cell viability was
analyzed on an Orion Microplate Luminometer with Simplicity soft-
ware (Berthold Detection Systems, Pforzheim, Germany).
Ethics Statement
The fresh human whole-blood samples used in this study were ob-
tained from healthy anonymous volunteers at the Transfusion Center
of Madrid (Spain). Appropriated informed consent was obtained
from each subject in accordance with the Spanish legislation on blood334 Molecular Therapy: Nucleic Acids Vol. 17 September 2019donor regulations, in compliance with the confidentiality and privacy
rules. The procedures carried out in this study were approved by the
Institute Ramón y Cajal for Health Research (IRYCIS) ethics commit-
tee, in compliance with the Declaration of Helsinki.
Bioinformatics Studies
Predicted target genes of selected miRNAs were recovered from
miRTarbase68 (http://mirtarbase.mbc.nctu.edu.tw/php/index.php/)
and miRDB69,70 databases (http://www.mirdb.org/). miRTarBase
has accumulated more than 360 thousand miRNA-target interac-
tions (MTIs), collected from the literature after filtering research
articles related to functional studies of miRNAs. The recently up-
dated MirDB includes 2.1 million predicted gene targets regulated
by 6,709 miRNAs. Targets genes were selected using as the criterion
that a gene had to have at least two positive computational predic-
tions with different algorithms or reported biological evidence.
Functional enrichment analysis was performed using GOstats
(http://gostats.com/) and Panther (http://www.pantherdb.org/) da-
tabases. A threshold of p < 0.001 was selected to filter significant
GO terms.71
Statistical Analysis
The Kruskal-Wallis test with Dunn’s post-hoc analysis or two-way
ANOVA with the Bonferroni post-test analysis was performed, using
Prism 5.0 (Graph Pad, San Diego, CA).
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